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Introduction {#sec005}
============

Globally, an estimated 150 million episodes of acute lower respiratory infection (ALRI) occur each year among children \[[@pone.0126593.ref001]\]. Most of these infections are caused by respiratory viruses, particularly in children under two years of age. Polymerase chain reaction (PCR)-based assays identify one or more viruses in 50--85% of pediatric ALRI episodes \[[@pone.0126593.ref002]--[@pone.0126593.ref009]\]. However, determining the clinical significance of detection of respiratory viruses from children using PCR can be challenging. Virus-virus coinfections and mixed viral-bacterial infections occur in 15--30% of cases \[[@pone.0126593.ref005],[@pone.0126593.ref010]\], and viruses can be detected in 25--45% of children in the absence of respiratory symptoms \[[@pone.0126593.ref005]--[@pone.0126593.ref007]\].

The incidence of pediatric ALRI is highest in low- and middle-income countries (LMICs) \[[@pone.0126593.ref001]\]. In sub-Saharan Africa alone, more than 35 million episodes occur each year, resulting in 500 000 deaths and straining of the health care systems of many of the world's poorest countries \[[@pone.0126593.ref001]\]. Real-time multiplex PCR is appealing for low-resource settings because this technology can be highly automated and is thus less laborious and expensive than conventional methods \[[@pone.0126593.ref011]\]. Recent studies using real-time PCR confirmed the substantial role played by respiratory viruses in pediatric ALRI episodes in LMICs \[[@pone.0126593.ref006]--[@pone.0126593.ref009]\]. However, few studies examined whether detection of respiratory viruses by PCR can predict ALRI outcomes in these settings.

We conducted prospective cohort and case-control studies to identify the viral etiologies of severe ALRI among infants and young children in Botswana, and examined whether identification of respiratory syncytial virus (RSV) and non-RSV viruses by PCR is associated with ALRI outcomes.

Methods {#sec006}
=======

Setting {#sec007}
-------

These studies were conducted in Gaborone, Botswana between April 2012 and August 2014. Botswana has a semi-arid climate, with a short rainy season that typically occurs from November to March. The country's HIV prevalence among adults aged 15--49 years is 21.9% \[[@pone.0126593.ref012]\]. *Haemophilus influenzae* type B (Hib) conjugate vaccine was included in the country's immunization schedule in 2010. Pneumococcal conjugate vaccine (PCV-13) was introduced in July 2012. The public sector operates 98% of health facilities in Botswana, including an extensive network of clinics and health posts in the Gaborone area \[[@pone.0126593.ref013]\].

Prospective Cohort Study {#sec008}
------------------------

We conducted a hospital-based, prospective cohort study to identify the viral etiologies of ALRI in Botswana and investigate their association with ALRI outcomes. Eligible children were 1--23 months of age presenting to a tertiary hospital with pneumonia, defined by the World Health Organization (WHO) as cough or difficulty in breathing with lower chest wall indrawing \[[@pone.0126593.ref014]\]. Children with one or more danger signs (central cyanosis, convulsions, inability to drink, or abnormal sleepiness) were classified as having severe pneumonia \[[@pone.0126593.ref014]\]. We excluded children with a chronic medical condition predisposing to pneumonia (other than HIV), hospitalization in the prior 14 days, asthma, or wheezing with resolution of lower chest wall indrawing after ≤2 bronchodilator treatments. All children were recruited within six hours of the triage time in the Emergency Department, and clinical care was provided by medical officers and pediatric residents on a ward supervised by pediatric specialists. Departmental guidelines for treatment of pneumonia were based on WHO recommendations, but antibiotic treatment decisions were ultimately at the discretion of the supervising pediatrician \[[@pone.0126593.ref014]\].

Sociodemographic and clinical data were collected at enrollment from physical examination, infant and maternal medical records, and a face-to-face interview with the child's caregiver(s). Research staff assessed children and reviewed charts daily until hospital discharge (or death). The primary outcome, treatment failure, was assessed at 48 hours by a study physician or nurse blinded to enrollment data. Treatment failure was defined as persistent lower chest wall indrawing, the development of new WHO danger signs, oxygen saturation \<80% (on room air), requirement for continuous positive airway pressure (CPAP) or mechanical ventilation, or death. This definition was adapted for our setting from criteria used in a previous study of childhood pneumonia \[[@pone.0126593.ref015]\], and training sessions were held every three months during the study period to standardize the assessment process. Cases discharged before 48 hours were considered treatment responders but caregivers were contacted by telephone to confirm treatment response. Secondary outcomes included days of respiratory support (supplemental oxygen, CPAP, or mechanical ventilation), length of stay, and in-hospital mortality.

Case-Control Study {#sec009}
------------------

In order to examine the strength of associations between detection of specific respiratory viruses and ALRI, we enrolled in parallel a group of community-based control subjects without ALRI. These controls were children 1--23 months of age receiving well child or acute care services at one of 18 public clinics in the Gaborone area. Controls were matched to pneumonia cases 1:1 by primary care clinic and date (≤2 weeks from the case enrollment). Exclusion criteria were WHO-defined pneumonia, a chronic medical condition predisposing to pneumonia (other than HIV), hospitalization in the prior 14 days, and asthma. Control children with and without symptoms of upper respiratory infection (URI; presence of rhinorrhea, nasal congestion, or cough) were enrolled. As with children enrolled in the pneumonia cohort, we collected enrollment data for controls from physical examination, infant and maternal medical records, and a face-to-face interview with the child's caregiver(s).

Children could be enrolled more than once as either a case or control subject provided that the second enrollment occurred ≥30 days after hospital discharge for a prior case enrollment or ≥30 days after the enrollment date for a prior control enrollment.

Laboratory methods {#sec010}
------------------

Nasopharyngeal swab specimens were obtained from cases and controls at enrollment using flocked swabs and universal transport media (Copan Italia, Brescia, Italy). These specimens were stored at -80°C and shipped on dry ice at 6-month intervals to the Regional Virology Laboratory (St. Joseph's Healthcare, Hamilton, ON, Canada). Testing for RSV, influenza viruses A and B, parainfluenza virus types 1--3, human metapneumovirus (hMPV), and adenovirus was performed using real-time multiplex PCR. Testing for enterovirus/rhinovirus (E/R) was conducted via a uniplex PCR assay, and positive samples were further characterized by sequencing of the amplicon to identify the species.

Statistical analysis {#sec011}
--------------------

We described baseline characteristics of case and control subjects using frequencies and percentages for categorical variables and medians and interquartile ranges (IQR) for continuous variables. We used chi-square tests conditioning on the matched pairs to compare baseline characteristics of case and control subjects. We used generalized estimating equations to account for correlated data among children enrolled more than once as either a case or control subject. To examine pneumonia outcomes by detection of respiratory viruses, we classified case subjects as having RSV only, RSV and non-RSV virus coinfection, non-RSV viruses only, or no respiratory viruses. We used Cox proportional hazards to directly estimate risk ratios for treatment failure at 48 hours and in-hospital mortality and linear regression to estimate mean differences in days of respiratory support and length of stay in comparing these groups \[[@pone.0126593.ref016]\]. Adjusted analyses included the following variables identified a priori based on a literature review: age, low birth weight, HIV exposure status, severe malnutrition, current breastfeeding, household use of wood as a cooking fuel, WHO disease severity, and hypoxia (oxygen saturation \<90% on room air) at enrollment \[[@pone.0126593.ref017]--[@pone.0126593.ref019]\]. For the matched case-control study, we used Fisher's exact test conditioning on the matched pairs to compare the frequency of detection of specific respiratory viruses among cases and controls.

Study data were managed using Research Electronic Data Capture (REDCap) tools hosted at The Children's Hospital of Philadelphia (Philadelphia, PA) \[[@pone.0126593.ref020]\]. All statistical analyses were conducted using SAS software version 9.3 (SAS Institute, Cary, NC). These studies were approved by the Health Research and Development Committee (Ministry of Health, Botswana) and institutional review boards at Princess Marina Hospital, the University of Pennsylvania, Duke University, and McMaster University. For both studies, written informed consent was obtained from a legal guardian after a detailed explanation of the study procedures.

Results {#sec012}
=======

Prospective Cohort Study {#sec013}
------------------------

We enrolled 310 children with pneumonia during the study period ([Table 1](#pone.0126593.t001){ref-type="table"}, columns 1 and 2). Median \[IQR\] age was 6.1 \[2.8, 13.3\] months, and 55% were male. One hundred and four (34%) children presented with severe pneumonia. One or more respiratory viruses were detected from 232 of 310 (75%) children ([Table 2](#pone.0126593.t002){ref-type="table"}, columns 1 and 2), including RSV only in 89 (29%), RSV and non-RSV virus coinfection in 18 (6%), and non-RSV viruses in 125 (40%). One hundred and six (34%) children failed treatment at 48 hours and 18 (5.8%) died. Median \[IQR\] length of stay for the 292 children surviving to hospital discharge was 3.8 \[1.9, 7.9\] days. One-hundred and eighty-five (60%) children received supplemental oxygen, 32 (10%) required CPAP, and five (2%) children were mechanically ventilated during the hospitalization.

10.1371/journal.pone.0126593.t001

###### Baseline characteristics of N = 310 children 1 to 23 months of age with pneumonia and N = 133 matched control children in Gaborone, Botswana, April 2012 to August 2014.

![](pone.0126593.t001){#pone.0126593.t001g}

                                                                                Pneumonia Cases   Matched Controls[^a^](#t001fn002){ref-type="table-fn"}                                             
  ----------------------------------------------------------------------------- ----------------- -------------------------------------------------------- ----- ---- ----- ---- ---- ---- ---- ---- -------
  **Demographics**                                                                                                                                                                                   
   Age, months (n = 310, n = 133)                                                                                                                                                                    0.40
    1--5                                                                        154               50                                                       65    49   58    44   20   30   38   57   
    6--23                                                                       156               50                                                       68    51   75    56   46   70   29   43   
   Male gender (n = 310, n = 133)                                               171               55                                                       76    57   68    51   39   59   29   43   0.32
   Birth weight \<2500 grams (n = 306, n = 133)                                 62                20                                                       28    21   24    18   11   17   13   19   0.53
   HIV exposure status (n = 306, n = 119)                                                                                                                                                            0.001
    HIV-unexposed                                                               193               63                                                       74    57   94    79   46   79   48   79   
    HIV-exposed, uninfected                                                     89                29                                                       47    36   25    21   12   21   13   21   
    HIV-infected                                                                24                8                                                        9     7    0     0    0    0    0    0    
  **Nutrition and infant feeding practices**                                                                                                                                                         
   Current breastfeeding (n = 310, n = 128)                                     126               41                                                       50    38   67    50   31   47   36   54   0.05
   Severe malnutrition[^e^](#t001fn006){ref-type="table-fn"} (n = 294, n = 0)   25                9                                                        14    11   \-    \-   \-   \-   \-   \-   NA
  **Socioeconomic factors**                                                                                                                                                                          
   Maternal education level (n = 310, n = 133)                                                                                                                                                       0.01
    None or primary                                                             35                11                                                       16    12   5     4    5    8    0    0    
    Secondary                                                                   211               68                                                       92    69   87    65   42   64   45   67   
    Tertiary                                                                    64                21                                                       25    19   41    31   19   29   22   33   
   Electricity in household (n = 310, n = 133)                                  197               64                                                       70    53   90    68   42   64   48   72   0.01
   Municipal or private water source (n = 310, n = 133)                         266               86                                                       110   83   123   92   60   91   63   94   0.01
   Refrigerator in household (n = 310, n = 133)                                 184               59                                                       65    49   88    66   42   64   46   69   0.004
   Use of wood as a cooking fuel (n = 310, n = 133)                             108               35                                                       37    28   22    17   11   17   11   16   0.03
  **Vaccination status**                                                                                                                                                                             
    *Haemophilus influenza* type B (Hib) vaccine (n = 308, n = 133)                                                                                                                                  0.36
    0 doses                                                                     55                18                                                       23    17   16    12   3    5    13   19   
    1--2 doses                                                                  84                27                                                       36    27   34    26   16   24   18   27   
    ≥3 doses                                                                    169               55                                                       74    56   83    62   47   71   36   54   
   Pneumococcal conjugate vaccine (n = 308, n = 133)                                                                                                                                                 0.59
    0 doses                                                                     172               56                                                       59    44   51    38   22   33   29   43   
    1--2 doses                                                                  64                21                                                       36    27   39    29   21   32   18   27   
    ≥3 doses                                                                    72                23                                                       38    29   43    32   23   35   20   30   

URI, upper respiratory infection; NA, not analyzed; WHO, World Health Organization

^a^Controls were matched to cases 1:1 by primary care clinic and date (≤2 weeks from the case enrollment).

^b^5 children were enrolled as case subjects twice and one child was enrolled as a case subject on three occasions.

^c^Defined as presence of rhinorrhea, nasal congestion, or cough.

^d^Wald χ^2,^ P-values; generalized estimating equations were used to account for correlated data among children enrolled more than once as case subjects.

^e^Weight-for-length \<-3 standard deviation on standard WHO growth curves, mid-upper arm circumference \<115mm (for children ≥6 months of age), or bilateral edema of nutritional origin.

10.1371/journal.pone.0126593.t002

###### Respiratory viruses detected using multiplex PCR of nasopharyngeal specimens from n = 310 pneumonia episodes among children 1 to 23 months of age and n = 133 matched control children in Gaborone, Botswana, April 2012 to August 2014.
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                           Pneumonia Cases   Matched Controls                                                                                           
  ------------------------ ----------------- ------------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- --- ---- --- ----------
  RSV                      107                                  35        35        26        2         2         2         3         0        0        \<0.0001
  Influenza virus          11                                   4         6         5         2         2         2         3         0        0        0.10
   A                                         7                       2         3         2         2         2         2         3         0        0   
   B                                         4                       1         3         2         0         0         0         0         0        0   
  Parainfluenza virus      17                                   5         7         5         2         2         2         3         0        0        0.10
   Type 1                                    2                       1         0         0         0         0         0         0         0        0   
   Type 2                                    3                       1         3         2         1         1         1         2         0        0   
   Type 3                                    12                      4         4         3         1         1         1         2         0        0   
  Human metapneumovirus    20                                   6         11        8         0         0         0         0         0        0        
  Adenovirus               4                                    1         0         0         0         0         0         0         0        0        
  Rhinovirus/enterovirus   97                                   31        40        30        40        30        26        39        14       21       \>0.99
   Rhinovirus A                              35                      11        15        11        16        12        12        18        4        6   
   Rhinovirus B                              7                       2         5         4         3         2         1         2         2        3   
   Rhinovirus C                              40                      13        14        11        12        9         8         12        4        6   
   Other                                     15                      5         6         5         9         7         5         8         4        6   
  Any virus                232                                  75        93        70        45        34        31        47        14       21       \<0.0001
  \>1 virus                24                                   8         6         5         1         1         1         2         0        0        0.03

PCR, polymerase chain reaction; URI, upper respiratory infection; RSV, respiratory syncytial virus; NA, not analyzed

^a^Defined as presence of rhinorrhea, nasal congestion, or cough.

^b^ *P* value estimated using Fisher's exact test.

Outcomes by detection of RSV and other respiratory viruses are shown in [Table 3](#pone.0126593.t003){ref-type="table"}. Compared with detection of non-RSV viruses, detection of RSV only was associated with treatment failure at 48 hours \[risk ratio (RR): 1.85; 95% CI: 1.20, 2.84\], a requirement for more days of respiratory support \[mean difference (MD): 1.26 days; 95% CI: 0.30, 2.22 days\], and longer duration of hospitalization \[MD: 1.35 days; 95% CI: 0.20, 2.50 days\]. However, in-hospital mortality was significantly lower among children with RSV only than among children with non-RSV viruses \[RR: 0.09, 95% CI: 0.01, 0.80\]. The outcomes of children with RSV only did not significantly differ from those with negative viral testing, although in-hospital mortality tended to be lower (*P* = 0.13).

10.1371/journal.pone.0126593.t003

###### Outcomes according to detection of RSV and other respiratory viruses among children 1 to 23 months of age with pneumonia in Gaborone, Botswana, April 2012 to August 2014.
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                                                                 n (%) or Median \[IQR\]   RR or MD (95% CI)[^a^](#t003fn002){ref-type="table-fn"}   *P*                     
  -------------------------------------------------------------- ------------------------- --------------------------------------------------------- ------- --------------- ------
  **RSV vs. non-RSV viruses**                                                                                                                                                
   Treatment failure at 48 hours                                                                                                                                             
    RSV only (n = 89)                                            40                        \(45\)                                                    1.85    (1.20, 2.84)    0.01
    RSV and non-RSV virus coinfection (n = 18)                   7                         \(39\)                                                    2.26    (1.06, 4.84)    0.04
    Non-RSV viruses (n = 125)                                    28                        \(22\)                                                    1       Ref             \-
   Days of O2, CPAP, or mechanical ventilation                                                                                                                               
    RSV only                                                     2                         \[0, 4\]                                                  1.26    (0.30, 2.22)    0.01
    RSV and non-RSV virus coinfection                            1                         \[0, 3\]                                                  0.91    (-0.76, 2.58)   0.28
    Non-RSV viruses                                              1                         \[0, 2\]                                                  0       Ref             \-
   Length of stay, days[^b^](#t003fn003){ref-type="table-fn"}                                                                                                                
    RSV only                                                     5.1                       \[2.1, 8.0\]                                              1.35    (0.20, 2.50)    0.02
    RSV and non-RSV virus coinfection                            4.0                       \[2.1, 9.0\]                                              1.40    (-0.59, 3.39)   0.17
    Non-RSV viruses                                              2.3                       \[1.2, 5.2\]                                              0       Ref             \-
   In-hospital mortality[^c^](#t003fn004){ref-type="table-fn"}                                                                                                               
    RSV only                                                     3                         (3.4)                                                     0.09    (0.01, 0.80)    0.03
    Non-RSV viruses                                              8                         (6.4)                                                     1       Ref             \-
  **RSV vs. no respiratory viruses**                                                                                                                 8       6.40            
   Treatment failure at 48 hours                                                                                                                                             
    RSV only (n = 89)                                            40                        \(45\)                                                    1.29    (0.88, 1.89)    0.19
    RSV and non-RSV virus coinfection (n = 18)                   7                         \(39\)                                                    1.37    (0.65, 2.88)    0.41
    No respiratory viruses (n = 78)                              31                        \(40\)                                                    1       Ref             \-
   Days of O2, CPAP, or mechanical ventilation                                                                                                                               
    RSV only                                                     2                         \[0, 4\]                                                  -0.06   (-1.94, 1.83)   0.95
    RSV and non-RSV virus coinfection                            1                         \[0, 3\]                                                  -0.56   (-3.64, 2.52)   0.72
    No respiratory viruses                                       2                         \[0, 6\]                                                  0       Ref             \-
   Length of stay, days[^b^](#t003fn003){ref-type="table-fn"}                                                                                                                
    RSV only                                                     5.1                       \[2.1, 8.0\]                                              -0.49   (-2.36, 1.39)   0.61
    RSV and non-RSV virus coinfection                            4.0                       \[2.1, 9.0\]                                              -0.39   (-3.41, 2.62)   0.80
    No respiratory viruses                                       5.1                       \[2.5, 13.0\]                                             0       Ref             \-
   In-hospital mortality[^c^](#t003fn004){ref-type="table-fn"}                                                                                                               
    RSV only                                                     3                         (3.4)                                                     0.18    (0.02, 1.64)    0.13
    No respiratory viruses                                       7                         (9.0)                                                     1       Ref             \-

RSV, respiratory syncytial virus; IQR, interquartile range; RR, risk ratio; MD, mean difference; CI, confidence interval; O2, supplemental oxygen; CPAP, continuous positive airway pressure; WHO, World Health Organization

^a^Risk ratios (or mean differences) estimated from Cox proportional hazards (or linear regression) models adjusted for age, low birth weight, HIV exposure status, severe malnutrition, current breastfeeding, household use of wood as a cooking fuel, WHO disease severity, and oxygen saturation \<90% (on room air) at enrollment.

^b^Analysis excludes children with severe malnutrition, defined as weight-for-length \<-3 standard deviations on WHO growth curves, mid-upper arm circumference \<115mm (for children ≥6 months), or bilateral edema of nutritional origin.

^c^No deaths occurred among the *n* = 18 children with RSV and non-RSV virus coinfection.

Case-Control Study {#sec014}
------------------

We matched a control subject to 133 of 310 (43%) pneumonia cases ([Table 1](#pone.0126593.t001){ref-type="table"}, columns 3--10). Median \[IQR\] ages of matched case and control subjects were 7.0 \[3.0--13.3\] and 6.4 \[4.0--12.2\] months, respectively. Compared with controls, matched cases had a higher rate of HIV infection or exposure (*P* = 0.001), lower maternal education levels (*P* = 0.01), and lived in households that were less likely to have electricity (*P* = 0.01), a municipal or private water source (*P* = 0.01), or a refrigerator (*P* = 0.004), and more likely to use wood as a cooking fuel (*P* = 0.03). Ninety-three of 133 (70%) cases and 45 of 133 (34%) matched controls had one or more respiratory viruses ([Table 2](#pone.0126593.t002){ref-type="table"}, columns 3--10). Among controls, a respiratory virus was detected from 31 of 66 (47%) controls with URI symptoms and 14 of 67 (21%) controls without URI symptoms. Only RSV (*P*\<0.0001) and hMPV (*P* = 0.001) were significantly more frequent among cases than controls, although influenza and parainfluenza viruses also tended to be more common among children with pneumonia. Virus-virus coinfections were more frequent among cases than controls (5% vs. 1%, *P* = 0.03), with RSV-rhinovirus accounting for 16 of 25 (64%) coinfections. Only E/R was detected from controls without current URI symptoms.

Seasonality of Pneumonia Cases {#sec015}
------------------------------

In [Fig 1](#pone.0126593.g001){ref-type="fig"}, the detection of respiratory viruses in children with pneumonia is shown by month of enrollment. Detection of RSV varied substantially by season, with the virus being identified from \>45% of cases with pneumonia from March to June and \<30% of cases for the remainder of the year. The increase in pneumonia enrollments during the early winter months coincided with a peak in RSV activity.

![Seasonal distribution of respiratory viruses detected from children 1 to 23 months of age with pneumonia in Botswana, April 2012 to August 2014.](pone.0126593.g001){#pone.0126593.g001}

Discussion {#sec016}
==========

We identified a potential viral etiology in 75% of young children with pneumonia in Botswana. Detection of RSV in pneumonia was associated with worse hospital outcomes but lower in-hospital mortality than detection of non-RSV viruses. RSV and hMPV were the only viruses that were detected more frequently in pneumonia cases than in control children.

RSV was previously reported to be associated with a protracted illness course among children with severe ALRI in developed countries \[[@pone.0126593.ref021],[@pone.0126593.ref022]\]. In 136 children hospitalized for ALRI in Sweden, RSV predicted an increased need for supplemental oxygen and a longer length of stay than non-RSV viruses \[[@pone.0126593.ref021]\]. Similarly, hospitalized children with RSV ALRI in the United States had a more severe course than children with negative viral testing \[[@pone.0126593.ref022]\]. Few data are available from LMICs, but respiratory virus detection was not independently associated with treatment failure or death in a hospital-based study of Kenyan children \[[@pone.0126593.ref019]\]. Notably, RSV and non-RSV viruses were not considered separately in multivariable analyses, although treatment failure rates did not significantly differ in bivariable analyses comparing children with RSV, non-RSV viruses, and negative viral testing \[[@pone.0126593.ref019]\]. Moreover, several studies in Africa previously suggested that the case fatality rate for severe RSV ALRI among HIV-negative children is low \[[@pone.0126593.ref023],[@pone.0126593.ref024]\]. However, this study is, to our knowledge, the first detailed examination of associations between detection of specific respiratory viruses and outcomes of severe childhood ALRI in LMICs. We performed analyses adjusted for age, illness severity, and several other potential confounding factors that are prevalent among children in sub-Saharan Africa, including severe malnutrition and HIV infection or exposure \[[@pone.0126593.ref017]--[@pone.0126593.ref019]\]. Our findings indicate that RSV is an independent risk factor for clinical non-response at 48 hours and is associated with more days of respiratory support and a longer length of stay than non-RSV viruses. However, detection of RSV reduced the risk of in-hospital mortality by 90% compared with non-RSV viruses. In-hospital mortality for RSV ALRI also tended to be lower than for children with negative viral testing, in whom bacterial pneumonia is presumably more likely.

Although these are the first published data on the viral causes of ALRI in Botswana, our findings are similar to those reported in other African countries. Respiratory viruses were detected by PCR in 60% of 805 Kenyan children hospitalized for pneumonia, with RSV and rhinoviruses being the most frequently identified \[[@pone.0126593.ref005]\]. In rural Mozambique, rhinoviruses, adenovirus, and RSV were detected in 41%, 21%, and 11% of children hospitalized for pneumonia \[[@pone.0126593.ref008]\]. Rhinoviruses and RSV were also the most frequently identified viruses in studies of pediatric respiratory infections conducted in South Africa \[[@pone.0126593.ref025]\] and Burkina Faso \[[@pone.0126593.ref004]\]. Moreover, despite a semi-arid climate, circulation of respiratory viruses was strongly seasonal with the timing of RSV season coinciding with what was recently reported in South Africa \[[@pone.0126593.ref009]\].

Several prior studies examined associations between detection of specific respiratory viruses by PCR and pediatric ALRI. RSV, influenza A, parainfluenza types 1 and 3, and hMPV were more common in Nepalese children seeking outpatient care for ALRI than in age-matched controls \[[@pone.0126593.ref002]\]. Similar findings were observed in a study conducted in Alaska that compared children hospitalized for ALRI with asymptomatic controls \[[@pone.0126593.ref026]\]. However, in two studies conducted in Kenya, only RSV was significantly more frequent in hospitalized children with pneumonia than in outpatient controls \[[@pone.0126593.ref005],[@pone.0126593.ref006]\]. A major strength of our study is that controls were matched to cases by enrollment date and primary care clinic. Although this meant that we enrolled a control in fewer than half of cases, this strategy accounted for the seasonality of respiratory virus circulation and ensured that cases and controls were closely matched on location of residence within the Gaborone area. The relatively low rate of detection of influenza and parainfluenza viruses in our cohort limited the comparisons for these viruses, but our results offer further evidence of the potential for both RSV and hMPV to cause severe ALRI. Finally, rhinovirus was frequent among cases, but equally frequent in controls. As rhinovirus can be associated with asymptomatic infection, URI, and ALRI, the case-control methodology we used may be limited for proving ALRI causality. Further community-based, prospective studies are needed to delineate the role of rhinovirus in ALRI.

Although detection of respiratory viruses by PCR may provide valuable prognostic information, there are little data that these assays alter clinical management. Antibiotic use was reduced in some \[[@pone.0126593.ref003],[@pone.0126593.ref027]\] but not all pediatric studies \[[@pone.0126593.ref022],[@pone.0126593.ref028],[@pone.0126593.ref029]\], while the effect on length of stay and hospital costs has also been variable \[[@pone.0126593.ref027],[@pone.0126593.ref028],[@pone.0126593.ref030]\]. Additional research on the cost-effectiveness of these assays is needed before use in individual patient management in LMICs can be recommended.

Our study has several limitations. First, it was conducted at a single hospital in Botswana, and the viral etiologies and outcomes of severe ALRI may differ in other settings. Secondly, we did not have a sufficient sample size to assess outcomes for individual viruses other than RSV, choosing instead to analyze non-RSV viruses collectively. Moreover, although outcomes for RSV and non-RSV virus coinfections were broadly similar to those with RSV only, the relatively few viral coinfections in our cohort precluded a formal comparison of outcomes in these groups. Prior studies examining disease severity or outcomes of RSV and non-RSV virus coinfections have yielded conflicting results \[[@pone.0126593.ref031]--[@pone.0126593.ref033]\]. Finally, testing for bacterial pathogens was not available, and it is possible that the varied outcomes of RSV and non-RSV viruses relate to differential rates of bacterial coinfection. However, data from developed countries indicate that the prevalence of concurrent bacterial infection in infants hospitalized with RSV ALRI is low (\<2%) in the absence of respiratory failure \[[@pone.0126593.ref034],[@pone.0126593.ref035]\].

In conclusion, respiratory viruses were detected from a substantial proportion of severe ALRI episodes among infants and young children in Botswana. Detection of RSV by PCR may help clinicians in LMICs identify children with severe ALRI who are likely to have a protracted illness course but are at low risk for death. Further research is warranted to determine whether this diagnostic testing might improve clinical management and is cost-effective in settings with limited resources.
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